ULI262
Developing a novel therapeutic for people with
familial adenomatous polyposis (FAP).
The problem
No drug for colorectal cancer prevention
Curileum discovered and is developing a novel, oral small molecule drug that addresses the root cause of colorectal cancer: mutations leading to abnormal cell production forming polyps and progressing to cancer.
Colorectal cancer is one of the most common and deadly cancers worldwide. Current strategies for prevention rely on periodic colonoscopies and surgical removal of polyps, which are costly, invasive and burdensome for patients. Despite regular surveillance of people with inherited risk, including those with FAP and Lynch syndrome, many still develop cancer.
Contact us to discuss potential investment opportunities
Why it matters
It starts with a polyp — and there is no drug to stop it
Our solution
ULI262 – a first-in-class colorectal cancer therapy drug
Our novel pan-PPAR agonist addresses these large, unmet needs in colorectal cancer prevention. ULI262 provides a new treatment for patients with FAP, high-risk individuals identified in screening programmes like those with Lynch syndrome, and patients who remain at an elevated risk of relapse after treatment.
By re-directing precancerous cells toward normal tissue, ULI262 may prevent progression to cancer – offering the first scalable, non-invasive pharmacological solution for colorectal cancer prevention.
Curileum is currently preparing for first-in-human clinical studies of ULI262 for FAP treatment. We expect the FDA will grant Orphan Drug Designation for the treatment of FAP, helping to expedite the clinical trial process and accelerate the timeline to treating patients in urgent need.